Literature DB >> 6604698

Further studies of the role of noncapsular antibody in protection against experimental Haemophilus influenzae type b bacteremia.

J L Shenep, R S Munson, S J Barenkamp, D M Granoff.   

Abstract

Serum antibody against polyribosylribitol phosphate, the capsular antigen of Haemophilus influenzae type b, confers protection against experimental Haemophilus infection. Antibodies against noncapsular antigens are also protective, but the antigenic specificity of the protective antibodies remains unknown. Antilipopolysaccharide antibody was prepared by immunization of rabbits with boiled H. influenzae type b cells. Antilipopolysaccharide antibodies present in these sera did not protect against experimental Haemophilus bacteremia in infant rats. Antisera were also prepared by immunization of rabbits with live H. influenzae type b bacteria. After absorption of anticapsular and antilipopolysaccharide antibodies, these sera contained antibody to several outer membrane proteins which were accessible on the intact bacterial surface as detected by radioimmune precipitation. These absorbed sera prevented experimental Haemophilus bacteremia in infant rats. Thus, antibodies against noncapsular, non-lipopolysaccharide determinants, possibly against one or more outer membrane proteins, confer protection against experimental H. influenzae type b disease. In contrast, antibodies against lipopolysaccharide are ineffective.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604698      PMCID: PMC264552          DOI: 10.1128/iai.42.1.257-263.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A.

Authors:  S W Kessler
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

2.  Electrophoretic resolution of the "major outer membrane protein" of Escherichia coli K12 into four bands.

Authors:  B Lugtenberg; J Meijers; R Peters; P van der Hoek; L van Alphen
Journal:  FEBS Lett       Date:  1975-10-15       Impact factor: 4.124

3.  Immunoadsorbents.

Authors:  J B Robbins; R Schneerson
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

4.  Reassessment of the role of bactericidal antibody in Hemophilus influenzae infection.

Authors:  R D Feigin; D Richmond; D W Hosler; P G Shackelford
Journal:  Am J Med Sci       Date:  1971-12       Impact factor: 2.378

5.  Immunity to Haemophilus influenzae type B: the nature of the bactericidal antibody in human blood.

Authors:  Y Mpairwe
Journal:  J Med Microbiol       Date:  1971-02       Impact factor: 2.472

6.  The paradox of Hemophilus infuenzae type B bacteremia in the presence of serum bactericidal activity.

Authors:  S Shaw; A L Smith; P Anderson; D H Smith
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

7.  The role of encapsulation and host age in the clearance of Haemophilus influenzae bacteremia.

Authors:  P F Weller; A L Smith; P Anderson; D H Smith
Journal:  J Infect Dis       Date:  1977-01       Impact factor: 5.226

8.  Human serum activities against Hemophilus influenzae, type b.

Authors:  P Anderson; R B Johnston; D H Smith
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

9.  The infant rat as a model of bacterial meningitis.

Authors:  E R Moxon; M P Glode; A Sutton; J B Robbins
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

10.  Production of Haemophilus influenzae b meningitis in infant rats by intraperitoneal inoculation.

Authors:  A L Smith; D H Smith; D R Averill; J Marino; E R Moxon
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

View more
  29 in total

1.  Conservation of epitopes in the oligosaccharide portion of the lipooligosaccharide of Haemophilus influenzae type b.

Authors:  P A Gulig; C C Patrick; L Hermanstorfer; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

2.  Outer membrane protein binding sites of complement component 3 during opsonization of Haemophilus influenzae.

Authors:  S V Hetherington; C C Patrick; E J Hansen
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

Review 3.  Antigenic diversity and gene polymorphisms in Haemophilus influenzae.

Authors:  J R Gilsdorf
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

4.  Complement component 3 binding to Haemophilus influenzae type b in the presence of anticapsular and anti-outer membrane antibodies.

Authors:  S V Hetherington; C C Patrick
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

5.  Cross-reactivity of surface-exposed epitopes of outer membrane antigens of Haemophilus influenzae type b.

Authors:  M R Loeb; K A Woodin
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

6.  Isolation and characterization of a mutant of Haemophilus influenzae type b deficient in outer membrane protein P1.

Authors:  R Munson; A Hunt
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

7.  Antibody to the outer membrane proteins is the dominant opsonic antibody in normal human serum against H. influenzae type b.

Authors:  S V Hetherington
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

8.  Comparison of methods for serotyping isolates of Haemophilus influenzae.

Authors:  C A Himmelreich; S J Barenkamp; G A Storch
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

9.  Cloning of the gene encoding the major outer membrane protein of Haemophilus influenzae type b.

Authors:  E J Hansen; F R Gonzales; N R Chamberlain; M V Norgard; E E Miller; L D Cope; S E Pelzel; B Gaddy; A Clausell
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

10.  Comparison of sodium dodecyl sulfate-polyacrylamide gel electrophoresis profiles and antigenic relatedness among outer membrane proteins of 49 Brucella abortus strains.

Authors:  D R Verstreate; A J Winter
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.